Reports Q2 revenue $0, consensus $140k. “We had a successful ASCO conference this quarter, with topline data presentation for obe-cel from the FELIX study highlighting low levels of immunotoxicity combined with a high complete remission rate and excellent CAR T expansion and persistence in adult patients with relapsed/refractory ALL. The attractive clinical profile driven by the unique CAR design combined with robust and reliable manufacturing have been the foundation for the successful outcome of the FELIX study,” commented Dr. Christian Itin, Chief Executive Officer of Autolus. “The Company is now focused on delivering a BLA filing to the US FDA by year end and the initial preparatory activities for a commercial launch in 2024, pending the necessary regulatory approvals.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUTL:
- Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
- Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
- Autolus Therapeutics appoints Dolski as CFO, Hersberger, Neville as SVPs
- Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
- Autolus Therapeutics’ obe-cel in leukemia featured in Nature Medicine